On April 14, 2026 BostonGene, developer of the leading AI foundation model for tumor and immune biology, and ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, reported a strategic partnership to accelerate the clinical development of IMGS-001, the company’s lead program. IMGS-001 is a cytotoxic immune checkpoint inhibitor targeting both PD-L1 and PD-L2, and is being studied in a phase 1a/b dose-escalation and dose-expansion safety and efficacy trial (NCT06014502) in patients with solid tumors that have failed to respond to standard of care therapies. This collaboration will investigate the effect of IMGS-001 on patients based on each patient’s comprehensive immune and genetic profile, which can help identify those patients most likely to respond.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"IMGS-001, through its multifunctional mechanism of both direct cell killing and PD-1 pathway blockade, has been specifically engineered to drive clinical benefit in patients with tumors resistant to current immunotherapies," said James Barlow, President and CEO of ImmunoGenesis. "BostonGene’s cutting edge technology can both elucidate the mechanism of action of the drug and identify those patients with unmet medical need most likely to benefit."
Through this collaboration, BostonGene will apply its AI-driven multiomic platform to perform deep molecular characterization of patients treated with IMGS-001. By integrating high-resolution spatial biology with systemic immune monitoring, the partnership will generate the critical data needed to visualize how IMGS-001 treatment may reshape the tumor microenvironment and identify specific biology to predict patient response. This data-driven approach moves beyond traditional biomarker analysis to deliver a system-level understanding of disease biology and therapeutic impact. It is expected to enable more precise patient selection, improve clinical decision-making, and accelerate the development of IMGS-001.
"We believe this partnership represents a significant leap beyond conventional clinical monitoring," said Charles Schweizer, PhD, Senior Vice President of Clinical Development at ImmunoGenesis. "By embedding BostonGene’s AI-powered insights into our clinical framework, we are decoding the precise cellular and molecular pathways driving clinical outcomes. This clarity will allow us to move with greater speed and precision, ultimately strengthening the potential of IMGS-001 to address unmet medical needs for patients with cold or immune excluded tumors."
The integration of BostonGene’s technology allows for a real-time assessment of how IMGS-001 can unlock anti-tumor immunity. By mapping the complex interactions between the immune system and the tumor, the two companies aim to eliminate the "trial and error" often associated with immunotherapy, ensuring the right patients receive the most effective treatment at the right time.
"Modern oncology demands a shift from broad application to data-driven precision," said Nathan Fowler, MD, Chief Medical Officer of BostonGene. "By combining our spatial and multiomic expertise with the innovative pipeline at ImmunoGenesis, we are defining the mechanism by which IMGS-001 overcomes immunotherapy resistance. This critical collaboration delivers important evidence needed to guide the next generation of precision immunotherapy."
(Press release, BostonGene, APR 14, 2026, View Source [SID1234664380])